Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Goto

Showing results (141-150 of 265) with videos related to

Pageof 27
Sort By:
Heart (British Cardiac Society)|November 1, 2016
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillationM Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
Open Heart|December 14, 2023
Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of strokeDeborah M Siegal, Frederik H Verbrugge, Anne-Celine Martin, et al.
Circulation|April 20, 2011
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease TrialStephen D Wiviott, Marcus D Flather, Michelle L O'Donoghue, et al.
JAMA|January 13, 2006
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosisDeepak L Bhatt, P Gabriel Steg, E Magnus Ohman, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 7, 2018
Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AFYukihiro Koretsune, Takuma Etoh, Yousuke Katsuda, et al.
Mayo Clinic Proceedings|October 4, 2011
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registryTelly A Meadows, Deepak L Bhatt, Christopher P Cannon, et al.
Stroke|July 1, 2021
Reexamination of the Embolic Stroke of Undetermined Source ConceptGregory W Albers, Richard Bernstein, Johannes Brachmann, et al.
Clinical Cardiology|October 30, 2013
Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH RegistryFátima Rodriguez, Christopher P Cannon, Ph Gabriel Steg, et al.
European Heart Journal|June 24, 2008
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 studyDominick J Angiolillo, Piera Capranzano, Shinya Goto, et al.
Journal of the American College of Cardiology|April 23, 2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51C Michael Gibson, Anjan K Chakrabarti, Jessica Mega, et al.
Pageof 27

Showing results (141-150 of 265) with videos related to

Sort By:
Pageof 27
Heart (British Cardiac Society)|November 1, 2016
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillationM Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
Open Heart|December 14, 2023
Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of strokeDeborah M Siegal, Frederik H Verbrugge, Anne-Celine Martin, et al.
Circulation|April 20, 2011
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease TrialStephen D Wiviott, Marcus D Flather, Michelle L O'Donoghue, et al.
JAMA|January 13, 2006
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosisDeepak L Bhatt, P Gabriel Steg, E Magnus Ohman, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 7, 2018
Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AFYukihiro Koretsune, Takuma Etoh, Yousuke Katsuda, et al.
Mayo Clinic Proceedings|October 4, 2011
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registryTelly A Meadows, Deepak L Bhatt, Christopher P Cannon, et al.
Stroke|July 1, 2021
Reexamination of the Embolic Stroke of Undetermined Source ConceptGregory W Albers, Richard Bernstein, Johannes Brachmann, et al.
Clinical Cardiology|October 30, 2013
Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH RegistryFátima Rodriguez, Christopher P Cannon, Ph Gabriel Steg, et al.
European Heart Journal|June 24, 2008
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 studyDominick J Angiolillo, Piera Capranzano, Shinya Goto, et al.
Journal of the American College of Cardiology|April 23, 2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51C Michael Gibson, Anjan K Chakrabarti, Jessica Mega, et al.
Pageof 27